Article info
PDFHow to understand it
Mitochondrial neurogastrointestinal encephalopathy disease (MNGIE)
- Correspondence to Simon R Hammans, Wessex Neurological Centre, Southampton General Hospital, Southampton, SO16 6YD UK;simon.hammans{at}nhs.net
Citation
Mitochondrial neurogastrointestinal encephalopathy disease (MNGIE)
Publication history
- Accepted July 29, 2020
- First published September 26, 2020.
Online issue publication
January 19, 2021
Article Versions
- Previous version (26 September 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Diagnosis and therapy in neuromuscular disorders: diagnosis and new treatments in mitochondrial diseases
- Transient clinical improvement of a mitochondrial neurogastrointestinal encephalomyopathy-like syndrome after allogeneic haematopoietic stem cell transplantation
- Rare pathogenic mutation in the thymidine phosphorylase gene (TYMP) causing mitochondrial neurogastrointestinal encephalomyelopathy
- The “new” mitochondrial disorders
- Mitochondrial disease: mimics and chameleons
- Recognition, investigation and management of mitochondrial disease
- Distal myopathy with cachexia: an unrecognised phenotype caused by dominantly-inherited mitochondrial polymerase γ mutations
- A young man with bilateral epilepsia intractable and partialis continua
- MNGIE with lack of skeletal muscle involvement and a novel TP splice site mutation
- Frequency of mitochondrial transfer RNA mutations and deletions in 225 patients presenting with respiratory chain deficiencies